Oxford Scientists Develop Vaccine Against Ebola Outbreak in DRC
Oxford scientists developing new vaccine to tackle Ebola outbreak within months
Mail Online
Image: Mail Online
Scientists at the Oxford Vaccine Group are developing a vaccine targeting the Bundibugyo strain of Ebola, which is currently causing an outbreak in the Democratic Republic of the Congo (DRC). With 750 suspected cases and 177 deaths reported, the World Health Organization has elevated the outbreak risk to 'very high.' The vaccine could be ready for clinical trials within months.
- 01The Bundibugyo strain of Ebola has a mortality rate of 30 to 50 percent and has caused only two previous outbreaks.
- 02The WHO has declared a public health emergency of international concern regarding the current outbreak.
- 03The vaccine utilizes ChAdOx1 technology, previously used for the Covid-19 vaccine, modified to target the Bundibugyo virus.
- 04The Serum Institute of India is prepared to mass-produce the vaccine once Oxford provides the necessary materials.
- 05Vaccination will focus on high-risk individuals, including healthcare workers and close contacts of confirmed cases.
Advertisement
In-Article Ad
Scientists from the Oxford Vaccine Group (OVG) are rapidly developing a vaccine for the Bundibugyo strain of Ebola, which is currently causing a significant outbreak in the Democratic Republic of the Congo (DRC). The outbreak has led to 750 suspected cases and 177 deaths, prompting the World Health Organization (WHO) to raise the risk level from 'high' to 'very high.' The OVG is leveraging the same technology used in its Covid-19 vaccine to create this new vaccine, which is designed to instruct the immune system to recognize and combat the Bundibugyo virus without causing infection. Although the vaccine is still in development, it could enter clinical trials in as little as two to three months. The WHO has emphasized the urgency of the situation, declaring a public health emergency of international concern. In preparation for potential mass production, the Serum Institute of India is ready to manufacture the vaccine as soon as Oxford supplies the necessary medical-grade materials. Vaccination efforts will be targeted at healthcare workers and individuals at high risk of exposure rather than the general population.
Advertisement
In-Article Ad
The development of an Ebola vaccine could significantly reduce the risk of further spread of the virus in the DRC, potentially saving lives and stabilizing the region.
Advertisement
In-Article Ad
Reader Poll
Do you believe that a vaccine can effectively control the Ebola outbreak in the DRC?
Connecting to poll...
More about World Health Organization

WHO Elevates Ebola Risk in Democratic Republic of Congo to 'Very High' Amid Rising Cases
Investing Australia • May 22, 2026

Ebola Outbreak in Congo Escalates as WHO Reports Rising Cases
Global News • May 22, 2026
India's Health Ministry Enhances Ebola Surveillance Amid Global Emergency
The Economic Times • May 22, 2026
Read the original article
Visit the source for the complete story.



